On Mar. 2, 2020,Gilead Sciences announced it had acquired Forty Seven Inc. for $95.50 per share in cash or $4.9 billion. Forty Seven is a clinical-stage immuno-oncology company, based in Menlo Park, CA, that develops therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licensed from Stanford University.